

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6275413

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
HOE YUNE JUNG	04/02/2020
JONG SU JEON	04/02/2020
BO BAE KIM	04/03/2020
HEON JONG LEE	04/03/2020
MOON KI SONG	04/06/2020
DO HYUN LEE	04/02/2020
RECEIVING PARTY DATA	
Name:	NOVMETAPHARMA CO., LTD.
Street Address:	(TREES BUILDING, NONHYEON-DONG) 13TH FLOOR, 727
Internal Address:	EONJU-RO, GANGNAM-GU
City:	SEOUL
State/Country:	KOREA, REPUBLIC OF
Postal Code:	06050
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16757575
CORRESPONDENCE DATA	
Fax Number:	(512)536-4598
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	5124745201
Email:	aoipdocket@nortonrosefulbright.com
Correspondent Name:	NORTON ROSE FULBRIGHT US LLP
Address Line 1:	98 SAN JACINTO BLVD.
Address Line 2:	SUITE 1100
Address Line 4:	AUSTIN, TEXAS 78701
ATTORNEY DOCKET NUMBER:	ELIP.P0106US/1001118816
NAME OF SUBMITTER:	MONICA WOZNIAK
SIGNATURE:	/MONICA WOZNIAK/
DATE SIGNED:	08/31/2020

PATENT

Total Attachments: 3

source=ELIP.P0106US_ASSIGNMENT#page1.tif

source=ELIP.P0106US_ASSIGNMENT#page2.tif

source=ELIP.P0106US_ASSIGNMENT#page3.tif

ASSIGNMENT

WHEREAS, the undersigned (individually "ASSIGNOR" and collectively "ASSIGNORS"), are named inventors of the patent(s)/application(s) identified below (collectively "Patent(s)"),

AND WHEREAS **NOVMETAPHARMA CO., LTD.**, having a place of business at ((Trees Building, Nonhyeon-dong) 13th Floor, 727, Eonju-ro, Gangnam-gu, Seoul 06050, Republic of Korea ("ASSIGNEE"), is desirous of acquiring all right, title and interest in and to the Patent(s);

FOR GOOD AND VALUABLE CONSIDERATION, the receipt, sufficiency and adequacy of which are hereby acknowledged, each ASSIGNOR does hereby:

IRREVOCABLY SELLS, ASSIGNS, AND TRANSFERS to the ASSIGNEE ASSIGNOR's entire right, title, interest throughout the world in, and right to claim priority to U.S. Application titled "**PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DIABETES, CONTAINING ZINC SALT, CYCLO-HISPRO AND ANTIDIABETIC DRUG AS ACTIVE INGREDIENTS**", which is a 371 national phase application of PCT/KR2018/012392, filed October 19, 2018, which claims priority to Korean Application No. 10-2017-0136242, filed October 20, 2017, including all information disclosed therein, such right, title, and interest including but not limited to the right to sue for injunctions and/or damages for any past, ongoing, and/or future infringement. For the avoidance of doubt, this sale, assignment, and transfer extends to all ASSIGNOR's right, title, interest in, and right to claim priority to all patents and applications (throughout the world) of any kind that claim priority to or otherwise issue from any of the Patent(s), including any and all divisional, continuation, continuation-in-part, continuing, extension, foreign, international, national phase, non-provisional, provisional, reexamination, reissue, renewal or substitute patents and/or patent applications;


WARRANTS AND COVENANTS that ASSIGNOR has the authority to enter this ASSIGNMENT agreement, and that ASSIGNOR has done nothing and will not do anything to impair the rights conveyed to ASSIGNEE by this Agreement;

COVENANTS that, when requested and at the expense of the ASSIGNEE, ASSIGNOR will carry out in good faith the intent and purpose of this Agreement, including but not limited to executing any and all documents in connection with the Patent(s) and any and all divisional, continuation, continuation-in-part, continuing, extension, foreign, international, national phase, non-provisional, provisional, reexamination, reissue, renewal or substitute patents, and/or patent applications claiming priority to, or based on any information disclosed in any of the Patent(s), including all rightful oaths, declarations, assignments, powers of attorney, and other papers; communicate to the ASSIGNEE all facts known to the ASSIGNOR relating to all information disclosed in the Patent(s) and the history thereof; and generally do everything possible that the ASSIGNEE shall consider desirable for vesting title to the Patent(s) and such patents and/or patent applications in the ASSIGNEE, and for securing, maintaining, and enforcing patent protection for the Patent(s) and such patents and/or patent applications;

WAIVES any right it has to challenge the adequacy of the consideration; and

AGREES that this Agreement is binding on ASSIGNOR's heirs, assigns, representatives, and successors.

ASSIGNORS

	<u>April 2, 2020</u>
Name: JUNG, Hoe Yune	Date
	<u>4.2.2020</u>
Name: JEON, Jong Su	Date
	<u>4.3.2020</u>
Name: KIM, Bo Bae	Date

ASSIGNEE

	<u>April 3, 2020</u>
Name: Sunwook Hwang	Date
Title: CEO/President	
NOVMETAPHARMA CO., LTD.	



Name: LEE, Heon Jong

April 3, 2020

Date

Name: SONG, Moon Ki

Date



Name: LEE, Do Hyun

April 2, 2020

Date

Name: LEE, Heon Jong

Date



Name: SONG, Moon Ki

4-6-2020

Date

Name: LEE, Do Hyun

Date